Pindolol availability in hypertensive patients with normal and impaired renal function.
Intravenous and oral pharmacokinetics of pinlolol were studied in 18 hypertensive patients-9 with normal renal function and 9 with impaired renal function. Analysis of data showed that a linear two-compartment model was suitable to describe the pindolol kinetics. Compared with patients with normal renal function, patients with chronic renal failure exhibited: (1) unchanged transfer rate constants and distribution volumes and (2) decreased total body clearance with decreased renal clearance and unchanged nonrenal clearance. Analysis of oral data by the Loo-Riegelman method showed that the pindolol absorption kinetic was not first order. Compared with patients with normal renal function, patients with chronic renal failure exhibited decreased fraction of dose effectively absorbed and increased initial rate of absorption. The initial rate of absorption was inversely correlated with the creatinine clearance. The study disclosed evidence that absorption was modified in chronic renal failure.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D003404:Creatinine / Q000652:urine; D006801:Humans; D006973:Hypertension / Q000378:metabolism* / Q000503:physiopathology; D007275:Injections, Intravenous; D007668:Kidney / Q000502:physiology* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000503:physiopathology; D007700:Kinetics; D008875:Middle Aged; D008954:Models, Biological; D010869:Pindolol / Q000008:administration & dosage / Q000378:metabolism*
D003404:Creatinine; D010869:Pindolol